中 國 醫 藥 大 學
臨床醫學研究所
碩士學位論文

論文題目

利用蛋白質分析法比較氣喘病人的CD4+T淋巴球在
穩定控制期與不穩定期間的差異

Proteomic Analysis of CD4+ T-lymphocytes in Patients
with Asthma between Controlled and Uncontrolled Level

指 導 教 授 ： 徐武輝 教 授

共同指導教授： 鍾景光 教 授

研 究 生：柯仰馨

中 華 民 國 九 十 八 年 七 月

摘要

背景：氣喘屬慢性發炎疾病，多數研究焦點放在引發發炎的機制。在氣喘病因學中，T-淋巴球衍生的細胞激素被廣爲討論。在後基因領域中，蛋白質分析技術快速發展且成爲基因領域裡重要的輔助工具。我們利用蛋白質分析法中兩個重要的技術：二維式膠片電泳分析法與蛋白質身份鑑定質譜分析，來比較氣喘病人從不穩定期到穩定控制期時 T-淋巴球蛋白質間的差異。

材料與方法：對連續 6 位到院表現爲不穩定氣喘患者抽血並萃取到 CD4+ T-淋巴球，患者在三個月內經藥物控制爲穩定性氣喘，再次抽血取得 CD4+ T-淋巴球。接著利用二維式膠片電泳分析法比較不穩定期氣喘與穩定控制期氣喘時 T-淋巴球蛋白質間的差異。對於在膠片上有明顯差異的小點，我們再取出並利用蛋白質身份鑑定質譜儀分析與比對資料庫來確定爲何種蛋白質。

結果：氣喘患者體內的 CD4+ T-淋巴球有超過一百個以上的小點顯現在二維式膠片上。這些小點經由考馬斯亮藍染色液染色後，兩組患者的小點分佈呈現類似情況，但是其中有 13 個小點卻出現有意義的差異表現。若以從不穩定控制組到穩定控制組來看，其中有 6 種蛋白質減少而 7 種蛋白質增加。

結論：經由蛋白質分析法的應用，確實讓我們發現在氣喘患者體內 CD4+ T-淋巴球在穩定控制期與不穩定控制期間的差異，我們需要更多數量與不同範疇的研究來確認何者爲氣喘發作的標記或作爲治療不穩定控制的方法。

關鍵字：氣喘、T-淋巴球、蛋白質分析法

Abstract

Background   As a chronic inflammatory disease, much of the research related to asthma has focused on proinflammatory mechanisms. T-lymphocyte (T-LC)-derived cytokines have been implicated in asthmatic pathogenesis. Proteomic technology has rapidly developed in the postgenomic era, and it is now widely accepted as a complementary technology to genetic profiling. We investigated the changes of proteins in T-LC of asthmatic patients from the uncontrolled to controlled level by using standard proteome technology: two-dimensional polyacrylamide gel electrophoresis (2D-PAGE), liquid chromatography/mass spectrometry (LC/MS), and a database search.

Methods   The proteins of CD4+ T-LC were isolated from the whole blood of six asthmatic patients with uncontrolled to controlled levels over three months. 2D-PAGE was performed and coomassie blue stained protein spots were comparatively analyzed between the uncontrolled and controlled groups using an image analyzer. Some differentially expressed spots were identified by LC-MS/MS and database search.

Results   More than 100 spots were identified in the 2D-PAGE gels from the CD4+ T-LC of the asthmatic patients. The general distribution pattern of the spots in the Coomassie blue-stained gel was similar in both groups, and 13 proteins showed different intensity, suggesting differential expression. Six protein spots in the CD4+ T-LC of the uncontrolled asthmatic patients were increased and 7 spots were decreased compared to those of the controlled subjects.

Conclusions   The proteomic examination of the CD4+ T-LC revealed some differentially expressed proteins in the uncontrolled and controlled asthmatic patients. The possibility of using the differentially expressed proteins as important biomarkers and therapeutic targets in uncontrolled asthmatic patients warrants further study.

Acknowledgements

目錄

Chapter 1 Introduction

1.1. Background

The recognition of asthma as a chronic inflammatory disease in the 1980s led to new paradigms for asthma pathogenesis and treatment. Asthma is characterized by recurrent dyspnea, coughing, wheezing, and reversible airway obstruction mediated by airway inflammation [1-3] in which a variety of cell types, including eosinophils [4], mast cells [5], and T lymphocytes [6] contribute to a complex pathologic process that causes airway remodelling and ultimately leads to compromised lung function. It has been estimated that 5% to 10% of patients with asthma have severe disease that is not effectively controlled by typical therapies, and these patients are at high risk of asthma-related death [7]. However, there is still little information on the pathophysiological mechanisms responsible for uncontrolled asthma. It is well known that T-lymphocytes (T-LC) play a critical role in the initiation, progression and persistence of allergic disease, including asthma [8]. The critical role of T_H2 cells in asthma is also now widely accepted [9]. Natural killer T (NKT) cells are also believed to play a role in allergen sensitization and pathologic states in asthma [10]. Recently, advances have been made in defining mechanisms that control inflammation and induce immune tolerance to specific antigens. Subsets of CD4+ cells known as T regulatory cells still play an important role in directing these processes [11], and recent experiments have begun to define crucial molecular and signalling pathways. However, the immunological basis of this disease is still controversial.

To understand the pathophysiologic mechanisms of disease, it is important to know which genes, gene transcripts, proteins, and metabolites are specifically expressed in the disease. Nair *et al* [12] stressed the importance of the protein synthesis from the expression because the proteins produced by genes are ultimately responsible for most biological functions. Especially, because proteins undergo many post-translational modifications that affect their structures and functions, their ultimate phenotypes often differ from genetic information. Use of proteomic techniques to identify disease-specific protein biomarkers is a powerful tool for defining prognosis of disease and gaining deep insights into disease

mechanisms in which proteins play a major role. Protein profiling has often been performed by the classical two-dimensional sodium dodecyl sulfate polyacryamide gel electrophoresis (2D-PAGE) based on the densitometric quantification of proteins visualized using dyes on gel. After in-gel enzymatic digestion of the subject protein spots, the resulting peptides are subjected to liquid chromatography/ mass spectrometry (LC/MS). Several proteome profiles of bronchial asthmatic lungs have been reported; however, most of them were from animal studies [13,14].

1.2. Purpose

The purpose of this study is to explore the differentially expressed proteins of the T-lymphocytes in patients with asthma between uncontrolled and controlled level with using 2D-PAGE and LC/MS.

Chapter 2 Methods

2.1. Materials

Six consecutive patients from 21 to 54 years of age (3 females, 3 males; mean age, 34 years; Table 1) with asthma were enrolled on presentation to the pulmonary medicine clinic at ST. Martin De Porres hospital, a regional hospital in central Taiwan from June through December 2008, which satisfied the American Thoracic Society criteria [15], and had asthmatic symptoms within 1 week before the first visit. Uncontrolled asthma was diagnosed according to the Global Initiative for Asthma guidelines [16]. Upon enrolment, all asthmatic patients underwent pulmonary function test, blood test for eosinophil count, chest radiography, and some necessary examinations for ruling out other pulmonary diseases. All subjects were non-smokers, and those who suffered from heart disease, autoimmune disease, endocrine disease, chronic liver and renal disease, and cancer were excluded. We also excluded both viral and bacterial infection-induced acute asthma according to the following signs: (i) no significant elevation of serum antibodies for influenza A and B virus; parainfluenza 1, 2, and 3 virus; and respiratory syncytial virus; (ii) no fever elevation; (iii) no purulent sputum; and (iv) no increased peripheral neutrophils and serum C-reactive protein. Concomitant with the initial evaluation was the initiation of management with nebulized [beta]-agonists with or without inhaled or systemic corticosteroids, oral theophylline, nedocromil, or cromolyn for at least 1 month. A blood specimen was obtained from each patient, and a standardized questionnaire of an action plan to maintain asthma control was administered by a trained investigator. The subjects who suffered from airway infection within 4 weeks immediately after the examinations were also excluded. The characteristics of the subjects are detailed in Table 1. Written informed consent was obtained from each subject before the study, and the study protocol was approved by the Institutional Review Board (IRB) of St. Martin De Porres Hospital.

For all participants, initial and subsequent therapies were ordered by the examining pulmonary medicine physicians. Three months later, these subjects had been free of symptoms of a respiratory infection and of any asthma exacerbation for at least the previous 4 weeks and had not used either inhaled

or systemic corticosteroids, nedocromil, or cromolyn for at least 1 month before the second evaluation. Data from these six patients that satisfied these criteria for controlled asthma were included in the analysis and blood specimens were obtained again for proteomics.

2.2. Design

Heparinized peripheral venous from each subject was collected in a sterile vacuum tube as enrolled in uncontrolled asthma and subsequently controlled subjects three months later. Peripheral blood mononucleated cells were separated from 40 ml heparinized blood after washed and centrifuged by 40 ml of Histopaqu1-1077 solution (Sigma-Aldrich, Inc.) and 80 ml of normal saline. CD4+ TLC were independently purified from each blood sample by the methods of a T-cell-negative isolation procedure with using monoclonal antibody (MACS; Miltenyi Biotec; J&H Technology Co. Ltd.). Twelve samples of TLC from six persons were prepared using the processes described below.

For protein extraction, the CD4+ TLC pellet of each person was washed and centrifuged with 12000 rpm, 10 min for three times to remove the serum. The cells were then treated with lysis buffer containing 7 M urea; 2 M thiourea; 4% CHAPS; and protease inhibitor. The mixture was then stored at -80℃ until analysis after protein concentration was determined using a commercial reagent (2-D Quant Kit, Amersham Biosciences, Cat. No. 80-6486-22).

Samples containing approximately 280 μg of total protein were precipitated with 2-D Clean-Up Kit (Amersham Biosciences, Cat. No. 80-6484-51) and resuspended in 250 μl rehydration buffer (7 M urea, 2 M thiourea, 4% CHAPS, 20 mM DTT, 1% IPG buffer, 0.002% Bromophenol Blue). The first-dimensional gel separation was carried out with 13 cm pH 3-10 IPG strips and iso-electric focusing (IEF) was performed using Ettan IPGPhor II (Amersham Biosciences) for 70 kVhr at 20℃. After IEF, strips were equilibrated for 15 min in 6 mmol/L urea, 2% sodium dodecyl sulfate, 50 mmol/L Tris-Cl (pH 8.8), and 20% glycerol containing 1% dithiothreitol, and then equilibrated again for 15 min in the same buffer containing 2.5% iodoacetamide. Equilibrated IPG strips were placed on top of vertical slabs of 12% polyacrylamide gels and run in a PROTEAN II xi Cell tank (Bio-Rad) at 35 mA per gel. The gels were visualized using Coomassie Brilliant Blue R250 staining. After staining, 2-D gels were scanned using Powerlook 1120 (UMAX, Fremont, CA, U.S.A).

NanoLC-MS/MS analysis was performed on an integrated nanoLC-MS/MS system (QSTAR XL)

comprising a LC Packings NanoLC system with an autosampler, and a QSTAR XL Q-Tof mass spectrometer (Applied Biosystems) fitted with nano-LC sprayer. Online nanoESI-MS survey scan and data dependent acquisition of CID MS/MS were fully automated and synchronized with the nanoLC runs under the full software control of AnalystQS. After data acquisition, the individual MS/MS spectra acquired for each of the precursors within a single LC run were combined and output as a single Mascot-searchable peak list file. The peak list files were used to query the NCBI database using the Mascot program with the following parameters: peptide mass tolerance, 150 ppm; MS/MS ion mass tolerance, 0.15 Da; allowing up to one missed cleavage. Only significant hits as defined by Mascot probability analysis will be considered initially. In addition, a minimum total score of 20 comprising of at least a peptide match of ion score more than 20 was arbitrarily set as the threshold for acceptance.

2.3. Statistic methods

The images of 2-D gels were analyzed and compared using ImageMaster^{TM}2D Platinum version 5.0 (Amersham Biosciences). Analyses of spot-intensity calibration, spot detection, background abstraction, and matching of approximately 12 2D-PAGEs were performed using software (ProteomWeaver; Definiens; Munich, Germany). All selected spots were present in all gels. The differentially expressed spots were analyzed with using Mann-Whitney *U* test (SPSS, version 10.0.05; SPSS; Chicago, IL). Correction for multiple comparisons was done according to the false discovery rate (FDR) method and p values larger than the FDR α value of 0.05 that was calculated using the software were considered statistically nonsignificant.

Chapter 3 Results

More than 100 spots were identified in the 2D-PAGE gels from the CD4+ TLC of the asthmatic patients from uncontrolled to controlled levels. The general distribution pattern of the spots in the coomassie blue-stained gels was similar in both groups (Fig. 1, top left and top right, percent matches: 95.91%). The spots in the area of pI 3 to 10, and molecular weight of 10 to 100 kd were analyzed by an image analysis program (ProteomWeaver). Protein spots of the uncontrolled and controlled asthmatic groups were compared, and 13 proteins showed different intensity, suggesting the differential expression. Among them, the intensities of 6 spots were significantly increased and the intensities of 7 spots were decreased in the uncontrolled group compared to the controlled group. The 13 selected spots of the 2D-PAGE of an asthmatic, non-smoking, 32-year-old woman are shown in Fig. 1, *bottom*, C.

After destaining, extraction, and lysis with trypsin, the individual spots were identified by LC/MS and this was followed by the MASCOT database search algorithm. On the list of 13 candidate proteins for each spot, the final protein was determined by comprehensively considering the corresponding experimental isoelectric point, the molecular masses, the number of matched peptides, and the sequence coverage. Six up-regulated and 7 down-regulated proteins in the uncontrolled asthmatic group were identified (Table 1).

Chapter 4 Conclusion

4.1. Discussion

In 2007, Jeong *et al.* [17] reported that proteomic examination of the peripheral T-lymphocytes revealed some differentially expressed proteins in the asthmatic patients. However, this is the first proteomic approach using the CD4+ TLC of blood in asthmatic patients and defining the difference in severity.

It is known that the asthmatic process that triggers the immune system can lead to excessive release of various cytokines and inflammatory mediators, which are produced by T-cells, infiltrated mononuclear cells, eosinophils, and local mast cells into the lung. Subsets of CD4+ cells known as T regulatory cells still play an important role in directing these processes [11], and recent experiments have begun to define crucial molecular and signalling pathways. But the aetiology of airway hyperresponsiveness, a cardinal feature of asthma, has not been fully elucidated. Therefore, we performed proteomic analysis of the CD4+ TLC of controlled and uncontrolled asthmatic patients.

In the study, we identified several proteins that were previously unknown or known to be associated with the pathogenesis of asthmatic exacerbation. Our study showed the increase of the heat shock protein (HSP)-70 and HSP-90 in CD4+ TLC from the uncontrolled asthmatic group to controlled level. HSP is a ubiquitous, abundant and conserved protein whose rate of synthesis is increased in response to cellular stress. It is often the target of humoral and T-cell-mediated immune responses to infection [18] and could protect tissue from the deleterious effects of numerous mediators, reactive oxygen species, or tumor necrosis factor-α. Several studies [19,20] have suggested that HSP is correlated with the severity of asthma exacerbation. It has also been proposed that the HSP-70 and HSP-90 chaperone associate with a range of cellular steroid receptor and may modulate the effectiveness of steroid in asthmatics [21].

Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein (YWHA) is highly conserved molecule that functions as intracellular adaptors in a variety of biological processes, such as signal transduction, cell cycle control, and apoptosis. It is also a HSP that protects cells against physiological stress as its new cellular function [22]. Our study also showed the up-regulated expression of

YWHA from the uncontrolled asthma group to controlled level.

Several cytoskeletal proteins were associated with the T-lymphocytes of asthma patients. Vimentin is a type III intermediate filament protein normally expressed in cells of mesenchymal origin and it attaches to the nucleus, endoplasmic reticulum, and mitochondria for the control of shape, motility and migration of mesenchymal cells [23]. The increased expression of vimentin was observed in the uncontrolled asthma patients in our study. The cytoskeletal change may illustrate the functional change in the T-lymphocytes of asthma exacerbation. β-actin, also a cytoskeletal protein, functions in cellular shape and anchorage where transmembrane glycoproteins link fibronectin in the extracellular matrix with actin microfilaments on the cytoplasmic side of the membrane [24]. It is not surprising therefore that cellular proliferation, activation, and/or differentiation induces up-regulation of β-actin expression in CD4+ TLC of the uncontrolled asthmatic group and subsequent cytoskeletal remodelling.

Lung alveolar epithelial cells could produce fibrinogen when induced with proinflammatory mediators. [25] Fibrin is formed when thrombin, generated by the coagulation cascade factors and cofactors, cleaves fibrinopeptides A and B from fibrinogen. The most powerful protein inactivator of surfactant, to the best of our knowledge, is fibrin [26] and immunohistochemically detected fibrin was seen along the luminal surface of the distal airways in a patient who died of status asthmatics. [27] Fibrinogen β-chain was also significantly increased in CD4+ TLC of the uncontrolled asthmatic group in this study.

The enolase 1 is a key glycolytic enzyme with highly conserved amino acid sequences from microbial organism to mammal [28]. This enzyme is ubiquitously expressed in nearly all cell types, including epithelial cells, endothelial cells, and hematopoietic cells [28]. Although enolase 1 is mainly a cytosolic protein, it is also expressed on cell surfaces and functions as a plasminogen receptors [28]. The enolase 1 was ever reported as an autoantigen associated with severe asthma [29] and upregulation of Enolase 1 has been detected in many types of human cancer. Its activity also increased in the uncontrolled asthmatic group in our study.

Peroxiredoxins are antioxidant enzymes involved in protein and lipid protection against oxidative

injury and in cellular signalling pathways regulating apoptosis. Peroxiredoxin 2 is a member of the mammalian peroxiredoxin family of thiol proteins that is important in antioxidant defences and redox signalling. The decreased expression of peroxiredoxin 2 was reported to be associated with enhanced sensitivity of Down syndrome neurons to reactive oxygen species [30]. In our study, the up-regulation of peroxiredoxin 2 was also observed in CD4+ TLC from the uncontrolled asthmatic patients to controlled level.

Rho GTPases are molecular switches that regulate many essential cellular processes, including actin dynamics, gene transcription, cell-cycle progression and cell adhesion. To date most progress has been made in the cytoskeleton field, and several biochemical links have now been established between GTPases and the assembly of filamentous actin. Rho GDP dissociation inhibitor beta (Rho-GDI beta), an inhibitor of Rho GTPase, is primarily expressed by hematopoietic cells. Rho-GDI beta was also observed to be down-regulated in interleukin-4(IL-4) treated T cells and IL-4 regulates the subsequent stages of T helper 2 cell mediated disease, such as allergies [31]. Our study also demonstrated that its activity increased in CD4+ TLC from the uncontrolled asthmatic patients to controlled level.

Nuclear DNA helicase II (NDH II) belongs to the DEXH helicase superfamily and is able to unwind both double-stranded DNA and RNA in the presence of one of the four ribo- or deoxyribonucleoside triphospates. In addition to transcription, NDH II has multiple physiological functions, such as in RNA processing and transport, in DNA repair, and also in tumorigenesis [32]. The helicase containing protein complexes may also facilitate the entry of transcriptional apparatus to the IL-4 responsive promoters [33]. However, change of NDH II might modify the exacerbation of asthma in a still unknown manner. Tropomyosins (Tm) are a group of proteins with multiple isoforms found in both muscle and nonmuscle cells and in association with the troponin complex play a central role in the actin-linked calcium regulatory system of muscle contraction [34]. The predominant colonic epithelial Tm isoform, hTm5, can induce both humoral (B-cells) and cellular (T-cells) response in patients with UC. Tm has also been described as relevant allergens [35]. Change of Tm 3 in CD4+ TLC was also observed in this study, but the relation of this protein with the asthmatic exacerbation is not yet clear. Calreticulin, a major Ca2+ binding

(storage) chaperone in the endoplasmic reticulum, is a key component of the calreticulin/calnexin cycle which is responsible for the folding of newly synthesized proteins and glycoproteins by binding monoglucosylated carbohydrate and for quality control pathways in the endoplasmic reticulum. Immunogenic death show that apoptotic cells also displaying calreticulin on their surface are processed by dendritic cells that induce a specific T cell–mediated immune response against these apoptotic cells. The expression of calreticulin, which is also formed in vascular smooth muscle cells and vascular endothelial cells exposed to hyperglycaemic conditions, underlies the process of down-regulation of glucose transport in vascular cells under high-glucose conditions [36]. The adaptive mechanism protects vascular cells against damaging effects of an uncontrolled influx of glucose in face of hyperglycemia. The expression of calreticulin precursor increased in CD4+ TLC from the uncontrolled asthma patients to controlled level in our study, the change could possibly interfered glucose metabolism to response to asthmatic exacerbation.

4.2. Limitations

From the above, it is apparent that proteomic analysis reveals differences in protein expression that come from the change in level of the asthma patients. Both strategies have unique strengths and limitations. 2D-PAGE resolves thousands of proteins in a single run, and provides crucial molecular weight and isoelectric point information on intact protein; however, identification of some proteins may be hindered by their expression in various forms and the data may be skewed toward the more abundant proteins in the sample. Otherwise, although we selected non-smokers and relatively young participants, it is known that depending on the different physiologic conditions, such as age, gender, physical activity and the disease status, 2D-PAGE can show different panels [12]. Finally, whether the changes of such proteins are pathognomonic markers of asthma or of a reactive phenomenon is questionable.

4.3. Suggestions

In summary, we have used 2D-PAGE/LC/MS to examine the protein profiles and expression in CD4+ TLC from uncontrolled and controlled asthma patients. Identification of these proteins revealed significant increase in expression for eight proteins, whereas six showed a significant reduction. These differences provide novel information highlighting proteins that may be linked to the mechanism(s) that defines why the asthma patients develop acute deterioration. The possibility of using the differentially expressed proteins as important biomarkers and therapeutic targets in uncontrolled asthma patients warrants further study.

Table 1. Demographics of Patients from Uncontrolled Asthmatics to Controlled Level

Age (yr)	Gender	Lung function (FEV1)	Presentation
32	F	47	Exacerbation
30	F	79	4 asthma features*
21	M	63	Exacerbation
32	M	66	3 asthma features
54	F	58	4 asthma features
35	M	71	Exacerbation

Definition of abbreviations: F = female; M = male; FEV1 = forced expiratory volume in the first second, expressed as the percentage of normal.

*Asthma features: daytime symptoms, limitations of activities, nocturnal symptoms/awakening, need for reliever/rescue treatment or abnormal lung function.

Table 2. Identification of the Proteins with Altered Expression Levels in the Human CD4+ T-Lymphocytes from the Uncontrolled Asthma Patients to Controlled Level*

No.	Protein Name	Mascot Program Access N0.	Exp	Seq Cov, %	T Mass, kd/pI	O Mass, kd/pI	%Vol Ratio	P Value
1	HSP-70	gi|16507237	↑	35	72/5.1	71/4.9	0.12/0.23	0.005
2	fibrinogen β chain	gi|119625338	↓	55	52/8.3	51/8.1	0.34/0.21	0.014
3	Tropomyosin 3	gi|24119203	↑	33	29/4.8	33/4.8	0.54/0.60	0.009
4	Unnamed protein product	gi|29446	↓	88	16/7.1	15/6.8	3.43/0/46	0.024
5	ATP-dependent DNA helicase II	gi|10863945	↓	12	83/5.6	99/6.1	5.34/1.37	0.036
6	HSP 90	gi|61656603	↑	18	98/5.1	98/4.7	0.25/0.71	0.001
7	β-actin	gi|4501885	↓	53	42/5.3	58/5.1	0.72/0.20	0.019
8	Vimentin	gi|62414289	↓	42	54/5.1	66/5.2	0.49/0.48	0.044
9	Rho GDP dissociation inhibitor beta	gi|56676393	↑	47	23/5.1	28/5.1	0.04/0.65	0.012
10	Enolase 1	gi|4503571	↓	48	47/7.0	51/7.2	0.70/0.18	0.022
11	Calreticulin precursor	gi|4757900	↑	13	48/4.3	66/3.9	0.13/0.31	0.001
12	Tyrosine 3-monooxygenase /tryptophan 5-monooxygenase activation protein	gi|4507949	↑	24	28/4.8	32/4.9	0.04/0.32	0.031
13	Peroxiredoxin 2	gi|32189392	↑	18	22/5.7	26.5.1	0.02/0.12	0.018

*Exp=expression; Cov=coverage; T=theoretic; O=observed; pI=isoelectric point; Vol=volume.

Figure 1. Representative 2D-PAGE gels of the CD4+ T-lymphocytes from uncontrolled asthma patients (*top left*) to controlled level (*top right*). Each image shows a similar expression pattern of spots between *top left* and *top right*. Thirteen selected and identified spots are shown by the numbered arrows in a 2D-PAGE gel (bottom) of an uncontrolled, asthmatic, 32-year-old woman.

References

1   Dunnill MS. The pathology of asthma, with special reference to changes in the bronchial mucosa. *J Clin Pathol* 1960; **13**:27-33

2   Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. *N Engl J Med* 1990; **323**:1033-1039

3   Laitinen A, Laitinen LA. Cellular infiltrates in asthma and in chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1991; **143**:1159-1160; discussion 1161

4   Vignola AM, Chanez P, Campbell AM, et al. Airway inflammation in mild intermittent and in persistent asthma. *Am J Respir Crit Care Med* 1998; **157**:403-409

5   Wardlaw AJ, Dunnette S, Gleich GJ, et al. Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma. Relationship to bronchial hyperreactivity. *Am Rev Respir Dis* 1988; **137**:62-69

6   Robinson DS, Hamid Q, Ying S, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. *N Engl J Med* 1992; **326**:298-304

7   The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. *Eur Respir J* 2003; **22**:470-477

8   Bian T, Yin KS, Jin SX, et al. Treatment of allergic airway inflammation and hyperresponsiveness by imiquimod modulating transcription factors T-bet and GATA-3. *Chin Med J (Engl)* 2006; **119**:640-648

9   Busse WW, Lemanske RF, Jr. Asthma. *N Engl J Med* 2001; **344**:350-362

10   Kim JO, Kim DH, Chang WS, et al. Asthma is induced by intranasal coadministration of allergen and natural killer T-cell ligand in a mouse model. *J Allergy Clin Immunol* 2004; **114**:1332-1338

11   Seroogy CM, Gern JE. The role of T regulatory cells in asthma. *J Allergy Clin Immunol* 2005; **116**:996-999

12   Nair KS, Jaleel A, Asmann YW, et al. Proteomic research: potential opportunities for clinical and physiological investigators. *Am J Physiol Endocrinol Metab* 2004; **286**:E863-874

13   Roh GS, Shin Y, Seo SW, et al. Proteome analysis of differential protein expression in allergen-induced asthmatic mice lung after dexamethasone treatment. *Proteomics* 2004; **4**:3318-3327

14   Fajardo I, Svensson L, Bucht A, et al. Increased levels of hypoxia-sensitive proteins in allergic airway inflammation. *Am J Respir Crit Care Med* 2004; **170**:477-484

15   Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. *Am Rev Respir Dis* 1987; **136**:225-244

16   Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. *Eur Respir J* 2008; **31**:143-178

17   Jeong HC, Lee SY, Lee EJ, et al. Proteomic analysis of peripheral T-lymphocytes in patients with asthma. *Chest* 2007; **132**:489-496

18   Shingai R, Maeda T, Onishi S, et al. Autoantibody against 70 kD heat shock protein in patients with autoimmune liver diseases. *J Hepatol* 1995; **23**:382-390

19   Aron Y, Busson M, Polla BS, et al. Analysis of hsp70 gene polymorphism in allergic asthma. *Allergy* 1999; **54**:165-170

20   Tong W, Luo W. Heat shock proteins' mRNA expression in asthma. *Respirology* 2000; **5**:227-230

21   Qian X, Zhu Y, Xu W, et al. Glucocorticoid receptor and heat shock protein 90 in peripheral blood mononuclear cells from asthmatics. *Chin Med J (Engl)* 2001; **114**:1051-1054

22   Yano M, Nakamuta S, Wu X, et al. A novel function of 14-3-3 protein: 14-3-3zeta is a heat-shock-related molecular chaperone that dissolves thermal-aggregated proteins. *Mol Biol Cell* 2006; **17**:4769-4779

23   Katsumoto T, Mitsushima A, Kurimura T. The role of the vimentin intermediate filaments in rat 3Y1 cells elucidated by immunoelectron microscopy and computer-graphic reconstruction. *Biol Cell* 1990; **68**:139-146

24   Blatti SP, Foster DN, Ranganathan G, et al. Induction of fibronectin gene transcription and mRNA is a primary response to growth-factor stimulation of AKR-2B cells. *Proc Natl Acad Sci U S A* 1988; **85**:1119-1123

25   Haidaris PJ. Induction of fibrinogen biosynthesis and secretion from cultured pulmonary epithelial cells. *Blood* 1997; **89**:873-882

26   Seeger W, Stohr G, Wolf HR, et al. Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer. *J Appl Physiol* 1985; **58**:326-338

27   Wagers SS, Norton RJ, Rinaldi LM, et al. Extravascular fibrin, plasminogen activator, plasminogen activator inhibitors, and airway hyperresponsiveness. *J Clin Invest* 2004; **114**:104-111

28   Pancholi V. Multifunctional alpha-enolase: its role in diseases. *Cell Mol Life Sci* 2001; **58**:902-920

29   Nahm DH, Lee KH, Shin JY, et al. Identification of alpha-enolase as an autoantigen associated with severe asthma. *J Allergy Clin Immunol* 2006; **118**:376-381

30   Sanchez-Font MF, Sebastia J, Sanfeliu C, et al. Peroxiredoxin 2 (PRDX2), an antioxidant enzyme, is under-expressed in Down syndrome fetal brains. *Cell Mol Life Sci* 2003; **60**:1513-1523

31   Rautajoki KJ, Marttila EM, Nyman TA, et al. Interleukin-4 inhibits caspase-3 by regulating several proteins in the Fas pathway during initial stages of human T helper 2 cell differentiation. *Mol Cell Proteomics* 2007; **6**:238-251

32   Friedemann J, Grosse F, Zhang S. Nuclear DNA helicase II (RNA helicase A) interacts with Werner syndrome helicase and stimulates its exonuclease activity. *J Biol Chem* 2005; **280**:31303-31313

33   Valineva T, Yang J, Silvennoinen O. Characterization of RNA helicase A as component of STAT6-dependent enhanceosome. *Nucleic Acids Res* 2006; **34**:3938-3946

34   Smillie LB. Preparation and identification of alpha- and beta-tropomyosins. *Methods Enzymol* 1982; **85 Pt B**:234-241

35   Aki T, Kodama T, Fujikawa A, et al. Immunochemical characterization of recombinant and native

tropomyosins as a new allergen from the house dust mite, Dermatophagoides farinae. *J Allergy Clin Immunol* 1995; **96**:74-83

36   Totary-Jain H, Naveh-Many T, Riahi Y, et al. Calreticulin destabilizes glucose transporter-1 mRNA in vascular endothelial and smooth muscle cells under high-glucose conditions. *Circ Res* 2005; **97**:1001-1008